Oramed and HTIT Form USD 75M U.S. Joint Venture
Oramed Pharmaceuticals, a Nasdaq- and Tel Aviv Stock Exchange-listed company, has established a joint venture in the U.S. with Chinese firm HTIT, transferring its operations and intellectual property rights related to oral insulin.
The agreement includes a USD 15 million investment from Oramed and USD 60 million from HTIT, aimed at advancing the development and commercialisation of oral insulin and other products based on Oramed’s POD™ technology.
Arnon, Tadmor-Levy represented Oramed in the transaction, with a legal team led by Daniel Green, Micki Shapira, Michael Horowitz, Asaf Tenenbaum, and Miriam Friedmann.
The deal strengthens Oramed’s strategic position in the diabetes treatment market, driving innovation in oral drug delivery solutions.
